ReviewFrontiers in medicine2021
Novel Therapies in Takayasu Arteritis.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Glomerulonephritis in Takayasu arteritis is dominated by mesangial and AA amyloid lesions and often arises during remission: a case-based review.Rheumatology international · 2026Pooled it
- Biologic therapies for the treatment of large vessel vasculitis: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Beyond the Pulselessness: A Multifaceted Case of Takayasu Arteritis With Aneurysmal Complications and Extensive Upper Limb Vascular Occlusion in a 40-Year-Old Female.Clinical case reports · 2025Article
- Article
- Acute Coronary Syndrome in a Young Woman With Takayasu Arteritis and Pancoronary Aneurysms.JACC. Case reports · 2025Article
- CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients.Clinical and experimental immunology · 2025Article
- The vasodilatory effect of acupuncture and medicine-cake-separated moxibustion on a 28-year course of Takayasu arteritis: a case report.Frontiers in cardiovascular medicine · 2025Article
- Amaurosis fugax in Takayasu arteritis mimicking migraine with visual aura.Proceedings (Baylor University. Medical Center) · 2025Article
- A challenging case of Takayasu's arteritis in a young male with various manifestations and poor outcome.BMC cardiovascular disorders · 2024Article
- Takayasu's Arteritis: A Special Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- High-throughput sequencing reveals the change of TCR α chain CDR3 with Takayasu arteritis.Immunity, inflammation and disease · 2023Article
- Advances and challenges in management of large vessel vasculitis.Rheumatology and immunology research · 2023Article
- Extracellular Matrix Remodeling in Vascular Disease: Defining Its Regulators and Pathological Influence.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Azathioprine-induced lymphoma in a patient with Takayasu arteritis: A case report from Iraq.Clinical case reports · 2023Article
- A patient with Takayasu arteritis presenting with malignant hypertension: a case report.European heart journal. Case reports · 2023Article
- Article
- Takayasu's Arteritis: Is Age a Differential Factor in the Diagnosis, Follow-Up, and Treatment of the Disease?Arquivos brasileiros de cardiologia · 2023Article
- A Rare Case of Takayasu Arteritis Presenting as Pericarditis with Effusion.Case reports in rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu Arteritis (TAK) is a large-vessel vasculitis that preferentially involves the aorta and its primary branches. Cardiac involvement is frequent in TAK and is a major determinant of the patient's outcome. Glucocorticoids (GC) are the mainstay of therapy for TAK, with high doses of GC effective to induce remission. However, relapses are common and lead to repeated and prolonged GC treatments with high risk of related adverse events. Potential GC toxicity is a major concern, especially because patients with TAK are young and need to be treated for several years, often for the whole life. Conventional immunosuppressive drugs are used in patients with severe manifestations but present some limitations. New therapeutic approaches are needed for patients with refractory disease or contraindications to conventional therapies. Fortunately, major progress has been made in understanding TAK pathogenesis, leading to the development of targeted biotherapies. In particular, IL-6 and TNF-α pathways seems to be the most promising therapeutic targets, with emerging data on Tocilizumab and TNF inhibitors. On the other hand, new insights on JAK-Inhibitors, Rituximab, Ustekinumab and Abatacept have been explored in recent studies. This review summarizes the emerging therapies used in TAK, focusing on the most recent studies on biologics and analyzing their efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.